NeurogesX (NGSX) -21.9% premarket following cautious reports related to FDA approval of its...

|By:, SA News Editor

NeurogesX (NGSX) -21.9% premarket following cautious reports related to FDA approval of its patch for HIV pain. The prescription-strength capsaicin patch didn’t meet its goals in studies for reducing pain caused by neuropathy linked to the virus, an FDA report says.